This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

13 Oct 2011

Gantenerumab Reduces Amyloid Levels in Alzheimer's Patients

A study demonstrates that two to seven months of treatment with gantenerumab led to dose-dependent amyloid reduction in the brains of patients with Alzheimer's disease.

Researchers from the F. Hoffmann-La Roche Ltd., Neuroscience in Basel, Switzerland said the medication gantenerumab appeared to reduce brain amyloid levels in patients with Alzheimer's disease, according to a preliminary study they had performed.


The study involved study subjects, who had mild-to-moderate Alzheimer's disease, at three university medical centers.


Two consecutive groups of patients were randomized to receive two to seven infusions of intravenous gantenerumab -- 60 mg or 200 mg -- or placebo every four weeks. Additionally, brain tissue from two patients who had Alzheimer's disease -- tissue obtained during tumor surgery -- was examined.


Related News